Abstract
Asymptomatic carriers contribute to the spread of Coronavirus Disease 2019 (COVID-19), but their clinical characteristics, viral kinetics, and antibody responses remain unclear. A total of 56 COVID-19 patients without symptoms at admission and 19 age-matched symptomatic patients were enrolled. RNA of SARS-CoV-2 was tested using transcriptase quantitative PCR, and the total antibodies (Ab), IgG, IgA, and IgM against the SARS-CoV-2 were tested using Chemiluminescence Microparticle Immuno Assay. Among 56 patients without symptoms at admission, 33 cases displayed symptoms and 23 remained asymptomatic throughout the follow-up period. 43.8% of the asymptomatic carriers were children and none of the asymptomatic cases had recognizable changes in C-reactive protein or interleukin-6, except one 64-year-old patient. The initial threshold cycle value of nasopharyngeal SARS-CoV-2 in asymptomatic carriers was similar to that in pre-symptomatic and symptomatic patients, but the positive viral nucleic acid detection period of asymptomatic carriers (9.63 days) was shorter than pre-symptomatic patients (13.6 days). There were no obvious differences in the seropositive conversion rate of total Ab, IgG, and IgA among the three groups, though the rates of IgM varied largely. The average peak IgG and IgM COI of asymptomatic cases was 3.5 and 0.8, respectively, which is also lower than those in symptomatic patients with peaked IgG and IgM COI of 4.5 and 2.4 (p < 0.05). Young COVID-19 patients seem to be asymptomatic cases with early clearance of SARS-CoV-2 and low levels of IgM generation but high total Ab, IgG, and IgA. Our findings provide empirical information for viral clearance and antibody kinetics of asymptomatic COVID-19 patients.
Highlights
An outbreak of the 2019 novel coronavirus disease (COVID19) has garnered international attention, rapidly spreading across the globe since it was first diagnosed in December of 2019
Earlier studies aimed to understand the infectiousness of asymptomatic carriers [8, 10, 11], the virological and immunological dynamics in these patients remain elusive
As highlighted in recent studies, COVID-19-specific mortality is age-related, with deaths mainly occurring in patients over 60 years old; while young patients usually present with moderate or mild manifestations of the disease [12]
Summary
An outbreak of the 2019 novel coronavirus disease (COVID19) has garnered international attention, rapidly spreading across the globe since it was first diagnosed in December of 2019. The infectiousness and transmission of the COVID-19 are worrisome to public health officials, as some cases have spread asymptomatically. Asymptomatic transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) has been documented [2, 3], with the proportion of cases attributed to asymptomatic transmission varying widely, with rates ranging from 1.2 to 50% [4, 5]. Asymptomatic infection refers to a person who has no clinical symptoms (such as fever, cough, or sore throat), yet test positive for the virus or serum antibody against SARS-CoV-2 [6]. Patients can be infected and transmit the disease without showing symptoms, suggesting that perhaps further isolation and continuous nucleic acid testing may be warranted after a patient is discharged [3]. As no vaccine has yet to be developed and treatment options are limited, identifying and containing the spread of these asymptomatic infections are key interventions that are necessary if governments and healthcare systems are to control the spread of COVID-19 and reduce disease-related mortality
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
